Akari Therapeutics announces presentation of mechanism of action data for PH1

Akari Therapeutics (AKTX) announced the presentation of immune mechanism-of-action data for its novel ADC payload, PH1. The Company will host a live webcast to discuss the presented data on Tuesday, November 18th. Key Highlights: Payload diversification is key in the current ADC landscape dominated by 2 ADC payload classes, microtubule inhibitors, and topoisomerase inhibitors. A payload that disrupts the actions of the spliceosome demonstrates multiple modes of actions to attack cancer, including cytotoxicity and broad immuno-oncology effects. An ADC of Trastuzumab PH1 induces RNA mis-splicing and subsequently increases neoantigen generation in cancer cells and a subsequent increase in anti-cancer immune cells in the tumor microenvironment. Trasutuzmab-PH1 in combination with an anti-PD1 agent outperformed Kadcyla in combination with an anti-PD1 agent in complete tumor regressions with statistical significance in an immune-competent, HER2-positive colon cancer model.